Although data from early phase trials suggest that retatrutide is well tolerated with a similar adverse event profile to GLP-1 RAs, additional research assessing long-term safety and efficacy of retatrutide in people living with obesity and/or T2D (including cardiovascular outcomes) is awaited over the next five years. The gene discussed is GCG; the disease is obesity disorder.